PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Chemotherapy - Market size and forecast 2018-2023 • Immunotherapy - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Improvements in research and development for treatment of relapsed refractory neuroblastoma • Availability of improved diagnostic modalities • Rising number of patient support initiatives PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb • Johnson & Johnson • Pfizer • Teva Pharmaceutical • United Therapeutics PART 14: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Pipeline molecules for neuroblastoma Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Immunotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Immunotherapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by product Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Decision framework Exhibit 42: Quarterly sales for UNITUXIN in $ millions Exhibit 43: Impact of drivers and challenges Exhibit 44: Novel therapies under research and development for neuroblastoma Exhibit 45: Patient support initiatives for neuroblastoma Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Bristol-Myers Squibb - Vendor overview Exhibit 52: Bristol-Myers Squibb - Business segments Exhibit 53: Bristol-Myers Squibb - Organizational developments Exhibit 54: Bristol-Myers Squibb - Geographic focus Exhibit 55: Bristol-Myers Squibb - Key offerings Exhibit 56: Johnson & Johnson - Vendor overview Exhibit 57: Johnson & Johnson - Business segments Exhibit 58: Johnson & Johnson - Organizational developments Exhibit 59: Johnson & Johnson - Geographic focus Exhibit 60: Johnson & Johnson - Segment focus Exhibit 61: Johnson & Johnson - Key offerings Exhibit 62: Pfizer - Vendor overview Exhibit 63: Pfizer - Business segments Exhibit 64: Pfizer - Organizational developments Exhibit 65: Pfizer - Geographic focus Exhibit 66: Pfizer - Segment focus Exhibit 67: Pfizer - Key offerings Exhibit 68: Teva Pharmaceutical - Vendor overview Exhibit 69: Teva Pharmaceutical - Business segments Exhibit 70: Teva Pharmaceutical - Organizational developments Exhibit 71: Teva Pharmaceutical - Geographic focus Exhibit 72: Teva Pharmaceutical - Segment focus Exhibit 73: Teva Pharmaceutical - Key offerings Exhibit 74: United Therapeutics - Vendor overview Exhibit 75: United Therapeutics - Business segments Exhibit 76: United Therapeutics - Organizational developments Exhibit 77: United Therapeutics - Geographic focus Exhibit 78: United Therapeutics - Key offerings Exhibit 79: Validation techniques employed for market sizing Exhibit 80: List of abbreviations  

Bristol-Myers Squibb Johnson & Johnson Pfizer Teva Pharmaceutical and United Therapeutics